Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$8.08 - $17.33 $4 Million - $8.59 Million
-495,500 Reduced 56.92%
375,000 $6.24 Million
Q4 2022

Feb 14, 2023

BUY
$2.72 - $9.4 $2.37 Million - $8.18 Million
870,500 New
870,500 $8.18 Million

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $5.05B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Octagon Capital Advisors LP Portfolio

Follow Octagon Capital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Octagon Capital Advisors LP with notifications on news.